Kamada Ltd.
KMDA
Rank in Stocks
#12941
Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies... Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies derived from blood plasma. Its operations are divided into two primary areas: developing and marketing its own proprietary products, and distributing a portfolio of third-party pharmaceuticals. Under its proprietary segment, Kamada develops and sells treatments such as KAMRAB/KEDRAB for rabies prevention, CYTOGAM for preventing cytomegalovirus in transplant recipients (including kidney, lung, liver, pancreas, heart, and heart/lung), WINRHO SDF for immune thrombocytopenic purpura (ITP) and to prevent Rh sensitization, HEPAGAM B for post-exposure prophylaxis and to stop hepatitis B recurrence after liver transplants, VARIZIG for post-exposure varicella prophylaxis, and GLASSIA, an intravenous therapy for Alpha-1 Antitrypsin Deficiency (AATD). Additional proprietary offerings include KamRho (D) IM for preventing hemolytic disease in newborns, KamRho (D) IV for immune thrombocytopenic purpura, and an antiserum specifically designed to treat snake bites from Vipera palaestinae and Echis coloratus. Through its distribution arm, Kamada provides a diverse portfolio of pharmaceuticals and medical devices. This includes BRAMITOB for chronic pulmonary infections, FOSTER for asthma management, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, the AEROBIKA OPEP device, RUPAFIN for allergic rhinitis and urticaria, IVIG for various immunodeficiency conditions, VARITECT for chickenpox and herpes zoster, ZUTECTRA and HEPATECT CP for hepatitis B, MEGALOTECT CP for cytomegalovirus, RUCONEST for angioedema attacks, heparin sodium injection for treating and preventing thromboembolic disorders, ALBUMIN for blood plasma, Factor VIII for hemophilia A, and Factor IX for hemophilia B. The distributed range also features IXIARO for Japanese encephalitis, VIVOTIF for Salmonella Typhi, PROCYSBI for nephropathic cystinosis, LAMZEDE for alpha-mannosidosis, and ELIGARD for prostate cancer. Kamada employs a multi-channel commercial strategy, utilizing strategic partners to market its products within the United States and relying on a network of distributors for its international sales. Key strategic alliances include collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, the company's headquarters are located in Rehovot, Israel.
Share Price
$7.43
Last synced: 2026-11-09
Market Cap
$428.49M
Change (1 day)
5.92%
Change (1 year)
4.03%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Kamada Ltd. (KMDA)
Category
Healthcare
Operating Margin for Kamada Ltd. (KMDA)
Operating Margin as of November 2026 TTM: 14.51%
According to Kamada Ltd.'s latest financial reports, its current operating margin (TTM) is 14.51%. At the end of 2025 the company had an operating margin of 14.54%.
Operating Margin history for Kamada Ltd. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 14.51% | -0.21% |
| 2025 | 14.54% | 16.69% |
| 2024 | 12.46% | 76.49% |
| 2023 | 7.06% | 101.71% |
| 2022 | 3.50% | -622.39% |
| 2021 | -0.67% | -104.64% |
| 2020 | 14.44% | -19.37% |
| 2019 | 17.91% | 6.48% |
| 2018 | 16.82% | 132.32% |
| 2017 | 7.24% | -196.02% |
| 2016 | -7.54% | -53.71% |
| 2015 | -16.29% | 7.45% |
| 2014 | -15.16% | -389.31% |
| 2013 | 5.24% | -10.12% |
| 2012 | 5.83% | -240.82% |
| 2011 | -4.14% | -86.01% |
| 2010 | -29.59% | -72.93% |
| 2009 | -109.31% | -2.42% |
| 2008 | -112.02% | -7.74% |
| 2007 | -121.42% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -97.34% |
US
|
|
| -149.01% | -110.27% |
US
|
|
| 25.57% | -98.24% |
AU
|
|
| 31.23% | -97.85% |
BE
|
|
| 29.35% | -97.98% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Kamada Ltd.'s operating margin
What is Kamada Ltd.'s operating margin?
Kamada Ltd.'s operating margin is 14.51%, as of Nov 2026.
What was Kamada Ltd.'s operating margin in 2025?
In 2025, Kamada Ltd.'s operating margin was 14.54%, compared with 12.46% in 2024.
How has Kamada Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Kamada Ltd.'s operating margin was highest in 2025 (14.54%) and lowest in 2021 (-0.67%).
How does Kamada Ltd.'s operating margin compare with similar companies?
Kamada Ltd.'s operating margin (14.51%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.